Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of
worsening of the respiratory system during the second week of the disease. To date,
treatments are currently being evaluated and none of them have shown to be effective in the
care of these patients. The use of convalescent plasma is a passive immunotherapy. It has
often been used in respiratory virus epidemic situations (during the 1918 or 2009 influenza
pandemic, or during SARS-CoV-1 or MERS-CoV pandemic). Effects reported in literature are in
favour of a beneficial impact of transfusion of these plasma without serious adverse effects
reported.
PlasCoSSA is a randomized, controlled, triple-blinded, parallel clinical trial. This study
tests the efficacy of convalescent plasma transfusion therapy in the early care of COVID-19
hospitalized patients outside intensive care units.